Nuvation Bio Inc. (NUVB)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nuvation Bio, Inc. (“Nuvation” or the “Company”) (NYSE: NUVB). Investors who purchased Nuvation securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Nuvation and certain of its officers and/or directors have violated federal securities laws.
On June 27, 2022, Nuvation issued a press release “announc[ing] the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer.” The press release stated that “[f]ollowing the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the Company proactively paused enrollment of new patients in order to further assess these adverse events with investigators and uveitis experts, and also reached out to the FDA for guidance around an appropriate path forward. While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.” On this news, Nuvation’s stock price fell $0.55 per share, or 13.13%, to close at $3.64 per share on June 27, 2022.
If you are aware of any facts relating to this investigation or purchased Nuvation shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.